Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA)...
Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug...
Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that velinotamig (project code:...
Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential
Duality Biologics (HKG: 9606) announced that it has entered into a global collaboration and license...
HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for...
AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline
AusperBio announced the completion of a USD 120m Series C financing round, a substantial capital...
Livzon Pharmaceutical’s Lecankitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis
Livzon Pharmaceutical (HKG: 1513) announced that lecankitug, jointly developed with Beijing Kanova Biopharma, has been...
TYK Medicines’ Asandeutertinib Wins NMPA Conditional Approval for EGFR-Mutant NSCLC with CNS Metastases
TYK Medicines (HKG: 2410) announced that its independently developed next-generation EGFR-TKI, asandeutertinib (TY-9591), has received...
AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn’s Disease
AbbVie (NYSE: ABBV) announced that it has submitted an application to the European Medicines Agency...
TÜV Rheinland and United Imaging Sign Strategic Cooperation MoU to Accelerate Global Market Access for Medical Devices
TÜV Rheinland Greater China and United Imaging Healthcare Co., LTD have signed a strategic cooperation...
ImmuneOnco Doses First Patient in Phase 2 Trial of IMM2510 Combo for First-Line HCC
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced that the first patient has been dosed in...
Asieris Wins EU CE Certification for APLD-2304, the World’s First Portable Single-Use Blue-Light Flexible Cystoscope
Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176) announced that its APLD-2304 flexible cystoscope has obtained...
China Health Report: NHC Data Shows Life Expectancy at 79.25 Years as Health Spending Reaches 6.7% of GDP
The National Health Commission of China (NHC) released the Statistical Bulletin on Health Development in...
Gilead’s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen
Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has...
Roivant’s Lisraya Wins FDA Approval as First Targeted Therapy for Dermatomyositis
Roivant (NASDAQ: ROIV) announced that the US Food and Drug Administration (FDA) has approved Lisraya...
Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked
Hansoh Pharmaceutical Group (HKG: 3692) released its interim results for the first half of 2026,...
HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%
China‑based HitGen Inc. (SHA: 688222) released its interim report for the first half of 2026,...
CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer
CSPC Pharmaceutical Group (HKG: 1093) announced that SYS6090 (JMT108), a PD‑1/IL‑15 bispecific fusion protein, has...
Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3
Insilico Medicine (HKG: 3696) released its interim results report for the six months ended June...
Huadong Medicine’s ROR1 ADC HDM2005 Granted FDA Fast Track Designation — First Domestic ROR1 ADC to Achieve the Status
Huadong Medicine (SHE: 000963) announced that its investigational drug HDM2005 has been granted Fast Track...